Paper Details

  1. Home
  2. Paper Details

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.

Author: ColombelJ-F, D'HaensG, PanaccioneR, PollackP F, RobinsonA M, SandbornW J, ThakkarR B, ZhouQ

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Prolonged adalimumab therapy maintained clinical remission and response in patients with moderately to severely active Crohn's disease for up to 4 years.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Therapies that maintain remission for patients with Crohn's disease are essential. Stable remission rates have been demonstrated for up to 2 years in adalimumab-treated patients with moderately to severely active Crohn's disease enrolled in the CHARM and ADHERE clinical trials. AIM: To ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670480/

データ提供：米国国立医学図書館（NLM）

Adalimumab: A Steady Hand Guiding Patients Through Crohn's Disease

The [treatment of Crohn's disease] is a complex journey, with patients facing the challenges of [inflammation and remission]. This study explores the long-term efficacy and safety of [adalimumab], a [biologic therapy], in managing [Crohn's disease]. The authors conducted a long-term analysis of data from the [CHARM and ADHERE clinical trials] and found that [adalimumab] maintained clinical remission and response in patients with [Crohn's disease] for up to [four years]. This is like finding a consistent and reliable source of water in the desert, offering stability and security for those navigating the challenging terrain of this chronic condition. The study also highlights the safety profile of [adalimumab], indicating that long-term use does not seem to pose a significant risk of adverse events.

Adalimumab: A Steady Source of Relief in the Desert of Crohn's Disease

The study provides encouraging evidence that [adalimumab] can help patients achieve and maintain [remission] in [Crohn's disease]. This is like finding a fertile oasis in the desert, offering a place of respite and healing. The long-term data provides reassurance for patients and clinicians, suggesting that [adalimumab] can be a reliable partner in the management of this complex condition.

Navigating the Desert of Crohn's Disease: A Reminder for Patients and Clinicians

It is important to remember that [Crohn's disease] is a diverse and unpredictable disorder, and treatment strategies need to be tailored to the individual needs of each patient. This is like recognizing that the desert is a vast and varied landscape, requiring different approaches for navigating its different terrains. Regular monitoring and open communication between patients and clinicians are essential for ensuring optimal treatment outcomes.

Dr. Camel's Conclusion

This study provides a valuable roadmap for navigating the desert of [Crohn's disease], showcasing the potential benefits of [adalimumab] in achieving and maintaining [remission]. It emphasizes the importance of personalized care and ongoing research to find the best possible solutions for patients with this complex condition.

Date :
  1. Date Completed 2014-09-26
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

24134498

DOI: Digital Object Identifier

PMC4670480

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.